A5037030903- Autoimmune Bullous Skin Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Urticaria and Related Conditions
- Cutaneous lymphoproliferative disorders research
- Eosinophilic Disorders and Syndromes
- Autoimmune and Inflammatory Disorders
- Platelet Disorders and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Dermatology and Skin Diseases
- Skin and Cellular Biology Research
- Oral Health Pathology and Treatment
- Celiac Disease Research and Management
- Chemotherapy-related skin toxicity
- Viral-associated cancers and disorders
- Oral and gingival health research
- CAR-T cell therapy research
- Dermatological and Skeletal Disorders
- Nail Diseases and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Dupuytren's Contracture and Treatments
- Systemic Sclerosis and Related Diseases
- Sympathectomy and Hyperhidrosis Treatments
- Drug-Induced Adverse Reactions
- Hidradenitis Suppurativa and Treatments
University of Florence
2017-2025
Philipps University of Marburg
2018-2024
Azienda Usl Toscana Centro
2021
Government of Western Australia Department of Health
2019
University of Bologna
2012-2014
Policlinico S.Orsola-Malpighi
2014
Istituto Oncologico Romagnolo
2014
Bullous pemphigoid (BP) is an autoimmune bullous disease caused by circulating autoantibodies toward the hemidesmosomal antigens BP180 and BP230. Cases of BP have been described following vaccinations against tetanus, poliomyelitis, diphtheria, influenza, pneumococcus, meningococcus, hepatitis B rabies. The putative mechanism which COVID-19-vaccines may induce has not clarified. An Italian multicentre study was conducted to collect clinical, histopathological immunopathological data patients...
Abstract Background Paraneoplastic pemphigus (PNP), also called paraneoplastic autoimmune multiorgan syndrome (PAMS), is a rare disease with mucocutaneous and multi‐organ involvement. PNP/PAMS typically associated lymphoproliferative or haematological malignancies, less frequently solid malignancies. The mortality rate of elevated owing to the increased risk severe infections disease‐associated complications, such as bronchiolitis obliterans. Objectives These guidelines summarize...
This study reports the efficacy of tralokinumab in 5 patients with bullous pemphigoid
Pemphigus and pemphigoid are two potentially life-threatening groups of autoimmune diseases, characterized by autoantibodies targeting structural components desmosomes or hemidesmosomes, respectively. Affected patients typically show itchy/painful plaques blistering skin lesions and/or impairing mucosal erosions, which may strongly impact their quality life. Since the milestone work Walter Lever in 1953, who differentiated these diseases histopathological analysis level antibody-mediated...
Bullous pemphigoid (BP) is the most frequent autoimmune blistering disease (AIBD) of skin [1]. Usually, BP affects patients in their seventh or eighth decade life and elicited by circulating immunoglobulin (Ig) G autoantibodies targeting BP180 (Collagen XVII) and/or BP230, two components dermo-epidermal junction (DEJ) In recent years, some unclear evidence rare sub-variants triggered pathogenic IgM directed against BP180, known as pemphigoid, have been reported. However, relevance...
Introduction: Paraneoplastic autoimmune multi-organ syndrome (PAMS) is a rare clinical condition characterized by variable and heterogeneous phenotypes in the presence of neoplasias which largely depend on activation humoral cellular immune responses. Clinically, these patients present with spectrum antibody-driven pemphigus-like lesions to graft-vs.-host-disease-like exanthemas lichenoid inflammatory infiltrate skin. PAMS occasionally associated thymoma, altered surveillance eventually...
Abstract Regarding primary mediastinal large B‐cell lymphoma (PMLBCL), there are several controversial topics that warrant further investigation: the superiority of third‐generation regimens, impact rituximab, use involved field radiotherapy (RT) and assessment clinical response by positron emission tomography (PET). We report our experience on 74 PMLBCL patients treated with a combination chemotherapy regimen (MACOP‐B) rituximab: an observational retrospective single‐centre study was...
Pyoderma gangrenosum (PG) is a rare, immune-mediated skin disease classified into the group of neutrophilic dermatoses. Although number studies confirmed central role innate immunity, only few have investigated possible contributing acquired immunity. In particular, no reports concerning T helper type 1 (Th1) and Th2 cells are available as yet. Therefore, 15 patients with PG, five Sweet's syndrome (SS) nine specimens from healthy controls (HC) were investigated, evaluating expression...
Vaccines are today considered one of the most effective means against Sars-CoV-2 pandemic. The BNT162b2 vaccine by Pfizer/BioNTech has been massively administered throughout globe; since its approval, a wide spectrum cutaneous reactions reported. Here we report case 52-year-old Caucasian male who presented with an acute febrile eruption that arose 72 h after first dose vaccine. clinicopathological findings were consistent Sweet's syndrome. short latency time suggested possible role in...
The definition of the role positron emission tomography (PET) in peripheral T-cell lymphomas (PTCLs) is still under investigation. purpose present observational retrospective study was to assess early prognostic value PET after first three cycles therapy (PET+3), evaluating visual data de novo PTCL patients treated line with standard chemotherapy and followed by both computed scan. Of 27 PET+3-negative patients, 19 also had a negative at end treatment (PET+6), whereas 8 positive final one; 6...
[See related article at [www.cmaj.ca/lookup/doi/10.1503/cmaj.170756][2]][2] A 21-year-old woman was admitted to a general medical ward with three-year history of self-limited episodes bleeding from her palms and face despite no evidence skin lesions. There obvious trigger for the
Abstract Bullous pemphigoid (BP) is an autoimmune bullous disease, characterized by autoantibodies targeting BP180 and BP230. The role of interleukin (IL)‐36, a potent chemoattractant for granulocytes, in BP remains elusive.The expression IL‐36 cytokines (IL‐36α, β, γ) their antagonists (IL‐36Ra IL‐38) was analysed the skin serum samples patients with ( n = 31), psoriasis 10) healthy controls (HC) 14) quantitative polymerase chain reaction enzyme linked immunosorbent assay, respectively....